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Stages of Institutional Review Board Activities
� EDITORIAL�
The modern medicine is characterized by continuous and
progressive changes from the incorporation and application
of newly acquired scientific knowledge. Most of time, the
final process of changes requires medical research involving
human subjects. The aim of scientific research in medicine is
to advance general knowledge by gathering evidence or data
for testing hypotheses. Then what actually occurs in scientif-
ic research in medicine is benefiting the mankind rather than
individuals. There are certain limitations to fulfill this utili-
tarian goal because the research participants that become a
means for a study are prone to exploitation, and are at poten-
tial risks.
In response to the atrocious deeds of Nazi’ s human exper-
imentation during the World War II, the Nurnberg Code was
promulgated in 1947 as the first international guidance on
permissible medical experimentation. The core statement in
the Nurnberg Code centers on the principle of informed con-
sent as ethical requirements for human research: “The vol-
untary consent of the human subjects is absolutely essential” .
In terms of moral responsibility, the Code presumes the pro-
tection of human subjects primarily at an individual inves-
tigator rather than at an institutional level. In the 1960s and
1970s, however, a succession of unethical researches, notably
as in Tuskegee Syphilis Study, was revealed. This alarmed that
the welfare and rights of human subjects could not be guar-
anteed by relying solely on the discerning investigators. Since
1974, after public outcries over scandalous human experi-
ments, the American Federal Government established the
regulations which require the beneficiary institutions review
of all biomedical and behavioral researches involving human
participants. This consists of prior approval and continuing
monitoring by Institutional Review Board (IRB). The Dec-
laration of Helsinki, which was first adopted by the World
Medical Association in 1964 and revised several times there-
after, also requires all biomedical research involving human
subjects to be reviewed by ethics review committees. Both
authors and publishers are responsible to publish papers the
studies that meet the ethical requirements of the Declaration
of Helsinki.
As a system to protect human subjects, the IRB review does
not depend solely on the responsibility of individual inves-
tigators. While investigators should abide by the ethical and
legal requirements of their research throughout its process of
initial study design, implementation, analysis and publica-
tion, the IRB review system requires research institutions to
take an official responsibility for ensuring human participant
protection by prospective and continuing review of research-
es conducted at each institution. International guidelines on
the IRB operation state clearly that the tenets of the IRB re-
view are independence, transparency and competency. Each
IRB should operate independently from investigators, spon-
sors, institutions, the professional community, or any other
undue influences. Since investigators have many legitimate
interests in the research, an independent review of the research
must intervene to minimize any conflicts. To reflect the ideal
of independence of IRB activity, the IRB should include at
least one non-medical person and another unaffiliated to the
institution. Independent review also reassures society that the
researchers will not take advantage by the abuse of partici-
pants. As such, the IRB offers a central role that ensures the
protection of human participants.
Recently, however, concerns about the system to protect the
right of human participants are rising worldwide. For the last
couple of decades, the tremendous development of biomedi-
cal research enterprises-with its increasing complexities and
commercial nature-pose great challenges concerning the pro-
tection of human participants and the restoration of public
trust. Therefore, international organizations and the developed
countries took the initiative and seriously examined the cur-
rent systems of human participants protection, including IRB
system, and decided to continue collaborative efforts to solve
the problems as it finds. The issue as to how to protect human
participants while maintaining public trust and promoting
scientific progress becomes both an international and a local
task.
In this issue of the Journal of Korean Medical Science, a spe-
cial article (2003; 18: 3-10) appears to describe the current
status of IRB operations in Korea. This article poses us with
a challenge by depicting the reality of shortcomings in IRB
performance, and by providing the reader with general pic-
ture of the state of research ethics in Korea. However, the early
stage of IRB activities and the lack of the experience in oper-
ating IRB are not necessarily an explanation why scandalous
medical researches have not been exposed. In fact, few med-
ical research scandals, unlike medical malpractice, have been
public issues in Korea. It has been culturally unimaginable
to design a medical research which may harm human par-
ticipants. Since the appalling exposure of unethical Japanese
military doctors’ experimentation involving the ethnic Kore-
ans during the wartime in China (Lancet 2002; Suppl; S5-6),
potentially harmful medical experiments have been regarded
as a crime. However, these general beliefs in medical research
fields in Korea do not verify that there has not been any indi-
vidual researcher’ s aberrant researches. In another aspect, the
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benevolent attitude toward research and the environment inad-
vertently have rather been a barrier for the medical researches
involving human participants in Korea. 
Since Korea abandoned the law that had granted to domes-
tic pharmaceutical firms a patent and marketing privilege for
a drug made by new synthetic process in 1987, the situation
of medical research involving human subject began to change.
Korean pharmaceutical firms should begin to find new mate-
rials as candidate drugs for human use. The change of phar-
maceutical industry in Korea urged Korean Government to
make a guideline in clinical trials of new candidate drugs,
and finally in 1995, the Korean Good Clinical Practice was
enacted in which clinical trials should abide by the IRB reg-
ulations. While these series of events developed in relation
with human research, many well recognized medical institu-
tions in Korea perceived quickly the importance of ethical
issues of human experimentation, began to form and actively
run IRBs since the late 1980s. Many medical institutes have
not formed their own IRB, and even if they have, they are at
the stages of growing experiences. Overall, the IRB activities
in this country are still in the early stages. In 2002, the Kore-
an Academy of Medical Sciences accepted the Korean Asso-
ciation of Institutional Review Boards as a sister organization
to promote its activities.
In the survey report of this issue on the operational prob-
lems of IRBs in Korea, it was found that the most serious one
is the scope of the review. Not all human related researches
are reviewed by IRBs. Also, there are many issues related with
the independence and the transparency of the activities. Con-
sidering the recent volume of biomedical research in Korea,
the academic research protocols reported as being reviewed
by this survey seems not to be on a level with the scope of
review intended by the Declaration of Helsinki. As the pro-
tection of research participants in biomedical research has
become a global issue, the medical researchers are requested
to abide by international standards of research practice more
rigorously. Therefore, it is further required in practice that
the research protocols should be approved at their births by
the designated IRBs, and the editors of medical journals re-
quest authors to explicitly state that their study was reviewed
by an ethics committee at the time when the paper is submit-
ted.
The Editor